Nile Therapeutics CEO takes token pay in cash crunch; Vivo Ventures invests $30M in China company;

Conversation on Twitter :

 @FierceBiotech: From FierceVaccines.com: PsiOxus lands $2.7M for ovarian cancer vaccine trial. Item | Follow @FierceBiotech

 @JohnCFierce: Buyout Buzz: The most frequently cited takeover targets in biotech. Special Report | Follow @JohnCFierce

 @RyanMFierce: Crowdsourcing kick spurs interest in NIH drug recycling. More | Follow @RyanMFierce

> The CEO at the tiny biotech Nile Therapeutics has slashed her pay to a token sum as the company scrambles to raise fresh funds. In a recent SEC filing Nile noted that it only had enough cash to make it through this month, according to a piece in the San Francisco Business Times. Story

> Vivo Ventures has invested $30 million in Shanghai Jingfeng Pharmaceutical. The move follows a decision to boost its investments in China with its seventh fund. Story

> Washington University researcher David Curiel has joined the scientific board at DNAtrix after merging his company with the Houston-based ovarian cancer drug developer. Story

Pharma News

@FiercePharma: Congressional hearings on the meningitis debacle to begin next week. FDA's Hamburg on the sked: Report | Follow @FiercePharma

> Teva shunts Americas chief aside in management shuffle. Article

> Bristol-Myers to slash 480 sales-related jobs in NJ. Story

> AbbVie raises $14.7B for spinoff in record bond issue. News

Medical Device News

 @FierceMedDev: After another quarterly slide, Wright Medical is planning to reorganize. Report | Follow @FierceMedDev

 @MarkHFierce: FDA warns the maker of a light therapy product designed to treat fungal meningitis that the product is unapproved. More | Follow @MarkHFierce

 @DamianFierce: Myriad Genetics is raising its full-year guidance after a strong quarter. More | Follow @DamianFierce

> FDA cites Tennessee company for meningitis light therapy device. Item

> St. Jude chases renal denervation market share with new study. Report

Biotech Research News

> Failed AstraZeneca drugs gain second chance with $11M U.K. program. News

> UC Davis team finds new lung cancer Rx target. Article

> 'Abdominal imaging window' lets researchers crack cancer metastasis secrets. Story

> Scientists wield stem cells to undo male infertility inflicted by cancer treatment in monkeys. More

Pharma Manufacturing News

> India's price-setting agency prepares for plant inspections. Story

> Sigma-Aldrich gets foothold in S. Korea with API deal. Article

> German Bayer partners with Russian drug manufacturer. News

And Finally… New research underscores the idea that some commonly used medications can trigger serious memory loss. Release

 

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.